Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bempedoic acid/ezetimibe - Esperion Therapeutics

Next Previous
Drug Profile

Bempedoic acid/ezetimibe - Esperion Therapeutics

Alternative Names: ETC-1002/ezetimibe; Ezetimibe/bempedoic acid; Ezetimibe/ETC-1002; NEXLIZET; Nustendi

Latest Information Update: 26 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Esperion Therapeutics
  • Developer Daiichi Sankyo Europe; Esperion Therapeutics; Neopharm Ltd
  • Class Antihyperlipidaemics; Azetidines; Dicarboxylic acids; Fatty acids; Fluorobenzenes; Propanols; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Cholesterol absorption inhibitors; Cholesterol synthesis inhibitors; NPC1L1 protein inhibitors; Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dyslipidaemias; Hypercholesterolaemia
  • Registered Cardiovascular disorders

Most Recent Events

  • 26 Nov 2025 CSL anticipates NDA approval for Cardiovascular disorders in Australia in the fourth quarter of 2026
  • 18 Nov 2025 HLS Therapeutics receives Notice of Non-Compliance from the Health Canada for Bempedoic acid/ezetimibe in Hypercholesterolaemia
  • 14 Aug 2025 Esperion therapeutics announces intention to launch Bempedoic/ezetimibe for Dyslipidaemia in Canada in the second quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top